Introduction
The neural crest is a transient structure in vertebrate embryos. Neural crest cells arise within the neural fold, migrate ventrally and laterally, and contribute significantly to a wide variety of cell types, including melanocytes, peripheral neurons and their glial cells, skeletal derivatives, and smooth muscle cells (Le Douarin and Kalcheim, 1999; Hall, 1999) . Mesencephalic neural crest cells migrate beneath the lateral ectoderm and populate the cranial ganglia or the mandibular arch to differentiate into neurons, glia, and chondrocytes (Kubota et al., 1996; Le Douarin and Kalcheim, 1999) .
We have demonstrated that Notch signaling activated by fibroblast growth factors (FGFs) acts on cells with different developmental potentials in the mouse mesencephalic neural crest cell population and affects their chondrogenic and gliogenic specification (Nakanishi et al., 2007; Ijuin et al., 2008) . Notch signaling is an evolutionally conserved mechanism that influences various biological processes, such as cell fate specification, differentiation, proliferation, and apoptosis (Artavanis-Tsakonas et al., 1999; Miele and Osborne, 1999) . Notch signaling is known to have different Notch receptor downstream pathways: RBP-J-dependent and Deltex-dependent pathways (Kato et al., 1997; Matsuno et al., 1995; . We have also shown that different Notch signaling pathways are required for the chondrogenic and gliogenic specification of mouse mesencephalic neural crest cells (Ijuin et al., 2008) . Whereas mammalian hairy 0925-4773/$ -see front matter Ó 2010 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2010.01.002 and enhancer of split homologues (Hes)-1 and Hes-5, which are target transcription factors of Notch signaling and regulate cell differentiation (Sasai et al., 1992; Ishibashi et al., 1994; Ohtsuka et al., 1999) , are activated by both the RBP-J and Deltex pathways in chondrogenic specification, these transcription factors are only stimulated by the Deltex pathway in gliogenic specification (Ijuin et al., 2008) . FGF signaling as well as Notch signaling has different downstream pathways (Carballada et al., 2001; Eswarakumar et al., 2005) . However, downstream pathways for FGF signaling that participate in the specification of mouse mesencephalic neural crest cells to chondrocytes and glia have not been identified. In the present study, therefore, we analyzed FGF signaling pathways that are responsible for chondrogenic and gliogenic specification.
Results

2.1.
Roles of the extracellular signal-regulated protein kinase (Erk) pathway in the specification of chondrocytes and glia
To examine which downstream pathways for FGF signaling activate Notch signaling, we analyzed the roles of the Erk pathway in chondrogenesis and gliogenesis. The Erk pathway is classified as a mitogen-activated protein kinase (MAPK) pathway, which is the major type of pathway activated by FGFs (Cobb et al., 1991) . Mouse mesencephalic neural crest cells were cultured in the presence or absence of FGF-2 and/or U0126, a specific inhibitor blocking the activation of Erk-1/2 by MAPK kinases (DeSilva et al., 1998) . Since the exposure to FGFs for the first 24 h in culture has been shown to be critical for chondrogenic specification (Nakanishi et al., 2007) , FGF-2 and/or U0126 were added during the first 24 h. After 7 days in culture, we performed immunocytochemistry using anti-collagen type II to detect proliferative and prehypertrophic chondrocytes (Nah et al., 1988) and counted the number of cells containing intracellular collagen type II to estimate the extent of chondrogenic differentiation. Whereas the percentage of cells expressing collagen type II per neural crest cell colony (each colony was derived from a primary explant) increased in the presence of FGF-2 as shown previously (Nakanishi et al., 2007) , U0126 significantly suppressed the expression of collagen type II in spite of the presence or absence of FGF-2 (Fig. 1A-C and G) . Furthermore, since the exposure to FGFs for the first 48 h in culture was essential for gliogenic specification (Ijuin et al., 2008) , the neural crest cells were cultured in the presence of FGF-2 and/or U0126 during the first 48 h and immunocytochemistry using anti-glial fibrillary acidic protein (GFAP) was carried out at 4 days in culture to detect glial differentiation. Gliogenesis was promoted in the presence of FGF-2 and prevented by the addition of U0126 (Fig. 1D-F and H) , similar to chondrogenesis. We used PD98059, another specific inhibitor blocking the activation of Erk-1/2 by MAPK kinases (Dudley et al., 1995) , to confirm these results. PD98059 prevented the expression of both collagen type II and GFAP, similar to U0126 ( Fig. 1G and H) . Furthermore, we used U0124, a negative control of U0126 , to examine the specificity of U0126. U0124 had no effects on chondrogenesis and gliogenesis ( Fig. 1G and H ).
Chondrogenesis and gliogenesis were significantly suppressed by the treatment with U0126 or PD98059 despite the presence or absence of FGF-2. This suggests that the culture medium containing fetal bovine serum (FBS) and extract of day 11 chick embryos (CEE) used in this study has FGF activity. To examine whether or not FBS and/or CEE contain(s) FGF activity, FGF signaling was prevented by SU5402, a specific inhibitor blocking FGF receptor tyrosine kinase activity (Mohammadi et al., 1997) , in the absence of FGF-2. Both chondrogenesis and gliogenesis were inhibited by SU5402 treatment ( Fig. 1G and H) .
2.2.
Erk-1 siRNA blocks the specification of chondrocytes and glia
To confirm that the Erk pathway participates in the chondrogenic and gliogenic specification, we blocked the Erk pathway by using Erk-1 siRNA. The expression of Erk-1 was suppressed by the treatment with Erk-1 siRNA during the first 24 h or 48 h in culture ( Fig. 2A-C and H ). Since Erk-1 siRNA treatment had no effects on the expression of Akt-1, another protein kinase that is activated by FGFs (Chan et al., 2000) , and a-tubulin expression ( Fig. 2D -G, I, and J), Erk-1 siRNA used in this study inhibits Erk-1 activity specifically. The expression of collagen type II or GFAP was significantly prevented by Erk-1 siRNA ( Fig. 2K and L) .
The Erk pathway activates Notch signaling
To examine that the promotion of chondrogenesis and gliogenesis by the Erk pathway is mediated by Notch signaling, the expression of Notch and Delta, a Notch ligand, was examined by immunocytochemistry using anti-Notch-1 and anti-Delta. Notch-1 expression was promoted by FGF-2 and significantly suppressed by the addition of U0126 (Fig. 3A-D) at both 24 h and 48 h in culture. However, no significant changes in the expression of Delta were found despite the presence of FGF-2 and/or U0126 ( Fig. 3E-H ).
2.4.
Ets-1 participates in the specification of chondrocytes but not of glia
The Erk pathway stimulates chondrogenesis and gliogenesis through Notch activation. Therefore, we analyzed the roles of Ets-1, which is a typical transcription factor activated by the Erk pathway (Rö ttinger et al., 2004; Stamatovic et al., 2006) , in chondrogenesis and gliogenesis. Mouse mesencephalic neural crest cells were transfected with full length Ets-1, dominant negative (dn) Ets-1, or Ets-1T38A, which is not phosphorylated by Erk-1 for a substitution of the threonine 38 residue to alanine (Paumelle et al., 2002) . Whereas the percentage of chondrocytes significantly increased by the transfection of full length Ets-1 during the first 24 h in culture, the transfection of dn Ets-1 prevented collagen type II expression (Fig. 4A) . Furthermore, Ets-1T38A also suppressed chondrogenesis (Fig. 4A) . Transfection of full length Ets-1 did not rescue the expression of collagen type II suppressed by U0126 (Fig. 4A) . These results are consistent with a previous report in which Ets-1 activation was shown to require phosphorylation by the Erk pathway (Paumelle et al., 2002 ). Since the promotion of chondrogenesis by full length Ets-1 in the absence of FGF-2 may be due to FGF activity in the culture medium containing FBS and CEE, the transfection of full length Ets-1 was carried out in the presence of SU5402. SU5402 treatment significantly suppressed the promotion of chondrogenesis by full length Ets-1 (Fig. 4A ). The treatment with the mouse Notch-1 intracellular domain (Notch-IC) expression vector restored the collagen type II expression prevented by dn Ets-1. By contrast, the transfection of full length Ets-1 or dn Ets-1 during the first 48 h in culture had no effects on the generation of glia (Fig. 4B ).
Since Ets-1 is also activated by the p38 MAPK pathway (Tanaka et al., 1998), we examined the roles of this pathway in chondrogenesis. However, the treatment with SB203580, a specific inhibitor of p38 MAPK, during the first 24 h in culture did not prevented chondrogenesis promoted by FGF-2 (Fig. 4A) . Thus, the activation of Ets-1 that participates in the chondrogenic specification is likely to be caused by the Erk pathway.
2.5.
Roles of the Akt pathway in the specification of chondrocytes and glia
Since Ets-1 is irrelevant to the specification of glia, another FGFs-dependent signal transduction pathway in addition to the Erk pathway may be implicated in gliogenesis. Therefore, we inhibited the Akt pathway, another signal transduction pathway that is activated by FGFs (Chan et al., 2000) , using LY294002 (a specific inhibitor that blocks Akt activation by inhibiting phosphatidylinositol 3-kinase; Vlahos et al., 1994) and rapamycin (a specific inhibitor that blocks p70S6 kinase (p70S6k) activation by inhibiting mammalian target of rapamycin (mTOR); Hosoi et al., 1999) . When these inhibitors were added to the neural crest cell cultures for the first 24 h or 48 h in culture, gliogenesis but not chondrogenesis was dramatically suppressed ( Fig. 4C and D) . We used LY303511, a negative control of LY294002 (Vlahos et al., 1994) , to examine the specificity of LY294002. This negative control had no effects on glio- genesis (Fig. 4C ). The treatment with the Notch-IC expression vector recovered the expression of GFAP prevented by rapamycin (Fig. 4C) . Furthermore, we inhibited the Akt pathway by Akt-1 siRNA. Akt-1 siRNA used in this study suppressed the expression of Akt-1 specifically (Fig. 4E-J) . Akt-1 siRNA prevented GFAP expression (Fig. 4K) . These results indicate that the Akt pathway as well as the Erk pathway is necessary for the gliogenesis of the mesencephalic neural crest cells.
2.6.
p70S6k affects the specification of glia p70S6k in the Akt pathway has at least eight phosphorylatable sites and the activation involves the sequential phosphorylation of residues by multiple protein kinases (Pullen and Thomas, 1997) . Phosphorylation of the Thr229 and Thr389 sites depends on the Akt pathway and Thr389 is phosphorylated by mTOR. Furthermore, phosphorylation of Thr389 requires phosphorylation of Thr421/Ser424 through the Erk pathway (Zhang et al., 2001; Lehman et al., 2003; Tsokas et al., 2007) . Thus, p70S6k is activated by both the Akt and Erk pathways. These previous data and the suppression of gliogenesis by rapamycin suggest that this kinase may play an important role in gliogenic specification.
To determine whether or not p70S6k participates in gliogenesis, we used p70S6k siRNA to block p70S6k activity specifically. The treatment with p70S6k siRNA during the first 48 h in culture significantly repressed phosphorylation of Thr421/ Ser424 and Thr389 sites in p70S6k (Fig. 5A-J) . Furthermore, p70S6k siRNA used in this study did not have off target effects ( Fig. 5K and L) . p70S6k siRNA treatment drastically prevented GFAP expression (Fig. 5M) .
Effects of various treatments on cell proliferation
We examined the effects of the treatments, which affected chondrogenesis and/or gliogenesis of mouse mesencephalic neural crest cells, on cell proliferation with the 5-bromo-2 0 -deoxyuridine (BrdU) incorporation method. There were no statistically significant differences with respect to the percentage of BrdU-incorporated cells under any of the treatments examined (Fig. 6) . Furthermore, no significant differences were found in the size of neural crest cell colonies. In the 4 0 6-diamidino-2-phenylindole (DAPI) nuclearstaining experiments, almost no cell death was observed under any of the conditions used.
Expression patterns of p70S6k in presumptive trigeminal ganglia
We examined the expression patterns of phospho-p70S6k (Thr421/Ser424), phospho-p70S6k (Thr389), and SOX10, which is a marker for undifferentiated neural crest cells (Kim et al., 2003) , in the presumptive trigeminal ganglionic region of the mouse embryo, where mouse mesencephalic neural crest cells colonize and undergo gliogenesis. Neighboring sections were immunostained by using anti-phospho-p70S6k (Thr421/Ser424) or anti-phospho-p70S6k (Thr389) and anti-SOX10. Cells expressing phospho-p70S6k (Thr421/Ser424), phospho-p70S6k (Thr389), and SOX10 were observed in the presumptive trigeminal ganglia of embryonic day (E) 8.5 and E9.5 embryos (Fig. 7) .
Discussion
3.1. Ets-1 activated by the Erk pathway in FGF signaling promotes the chondrogenic specification of mouse mesencephalic neural crest cells
The Erk pathway is a signaling pathway conserved from yeast to vertebrates and involved in multiple physiological processes, including cell proliferation, cell differentiation, and apoptosis (Schaeffer and Weber, 1999; Pearson et al., 2001; Peyssonnaux and Eychè ne, 2001 ). This pathway has been shown to participate in Notch-mediated oncogenesis (Fitzgerald et al., 2000) and to modulate chondrogenic differentiation (Muraka- Bobick and Kulyk, 2006) . In the present study, treatment with the Erk pathway inhibitor, U0126, blocked the promotion of Notch-1 expression and chondrogenesis by FGF-2 in mouse mesencephalic neural crest cell cultures. Moreover, Erk-1 siRNA inhibited chondrogenesis. Since FGFs promote the chondrogenic specification of mouse mesencephalic neural crest cells through the activation of Notch signaling (Sarkar et al., 2001; Nakanishi et al., 2007; Ijuin et al., 2008) , these data suggest that FGFs activate Notch signaling by means of the Erk pathway and the activation promotes the chondrogenic specification of the neural crest cells (Fig. 8) .
b M E C H A N I S M S O F D E V E L O P M E N
Ets-1, which is a transcription factor activated by the Erk pathway, plays important roles in neural crest cell migration (Théveneau et al., 2007) . Whereas the transfection of the full length Ets-1 expression vector promoted the chondrogenesis of the neural crest cells, dn Ets-1 and Ets-1T38A suppressed the promotion of chondrogenesis by FGF-2. Furthermore, the chondrogenic differentiation suppressed by dn Ets-1 was restored by the addition of Notch-IC expression vector and the inhibition of the p38 MAPK pathway had no effects on chondrogenesis. These results suggest that Ets-1 activation requires the phosphorylation of the threonine 38 residue by Erk-1 and the activated Ets-1 promotes the chondrogenic specification of neural crest cells through Notch activation (Fig. 8) . Ets-1 is also expressed in the sclerotome, another well-known region with chondrogenic properties (Fafeur et al., 1997; Tahtakran and Selleck, 2003) . This supports our present results. It has been proposed that a lateral nonneural domain of the neural fold epithelium, metablast, is a developmental source of skeletogenic and connective tissue mesenchyme (Breau et al., 2008) . Since the cultures used in this study may contain metablast, Ets-1 may be implicated in chondrogenesis of metablast.
3.2.
p70S6k activated by both the Erk and Akt pathways in FGF signaling promotes the gliogenic specification of mouse mesencephalic neural crest cells
Since FGFs promote the gliogenic specification of mouse mesencephalic neural crest cells through the activation of Notch signaling (Ijuin et al., 2008) , we analyzed FGF signaling pathways in the gliogenesis of these cells. The treatment with U0126 or Erk-1 siRNA suppressed gliogenesis as well as chondrogenesis. These results show that the Erk pathway also participates in the gliogenesis of neural crest cells. However, the transfection of full length Ets-1 or dn Ets-1 had no effects on gliogenic differentiation. On the other hand, the treatment with LY294002, which is a specific inhibitor blocking the Akt pathway, suppressed the promotion of gliogenesis but not chondrogenesis by FGF-2. Furthermore, Akt-1 siRNA prevented gliogenesis. Thus, both the Erk and Akt pathways were implicated in gliogenesis. These data suggest that p70S6k, which is activated by these pathways, may play an essential role in gliogenesis. p70S6k regulates cell growth (Gerasimovskaya et al., 2005; Zahr et al., 2007) , adipocyte differentiation (Gagnon et al., 2001) , and hematopoietic differentiation (Kanayasu-Toyoda et al., 1999; Yamamoto-Yamaguchi et al., 2001 ). The treatment with rapamycin, a specific inhibitor of this kinase, blocked gliogenic differentiation. Furthermore, p70S6k siRNA drastically suppressed gliogenesis. Since gliogenesis suppressed by rapamycin was rescued by the addition of Notch-IC expression vector, p70S6k activated by both the Erk and Akt pathways may promote the gliogenic specification of neural crest cells through Notch activation (Fig. 8) . The mouse presumptive trigeminal ganglia contained undifferentiated neural crest cells expressing SOX10, which contained p70S6k phosphorylated by both the Erk and Akt pathways. This result suggests that the activation of p70S6k by these pathways occurs in the neural crest cells in the presumptive trigeminal ganglia.
In this study, no significant differences were observed in the percentage of BrdU-incorporated cells, in the size of neural crest cell colonies, and in the extent of cell death under any of the culture conditions examined. These observations suggest that the extent of cell proliferation, survival, and death is unchanged under the present culture conditions. Furthermore, we have previously shown that the promotion of chondrogenesis and gliogenesis by FGF treatment and Notch activation is not due to selective proliferation of particular cells (Nakanishi et al., 2007; Ijuin et al., 2008) . Therefore, the present data are not likely to reflect selective proliferation, survival, and death of particular cell types. The percentage of chondrocytes and/or glia in the cultures treated with the specific inhibitors or siRNAs was significantly lower than that in the control cultures despite the presence or absence of FGF-2. Furthermore, SU5402 treatment prevented chondrogenesis and gliogenesis in the absence of FGF-2. On the other hand, exogenous FGF-2 enhanced chondrogenesis and gliogenesis. These results suggest that the culture medium containing FBS and CEE used in this study has a low level of FGF activity and that FGFs promote the chondrogenic and gliogenic specification in a dose dependent manner.
We have shown that FGFs promote both chondrogenic and gliogenic specification by means of Notch activation (Nakanishi et al., 2007; Ijuin et al., 2008) but Notch signaling pathways are different between chondrogenesis and gliogenesis (Ijuin et al., 2008) . Furthermore, the present data indicate that FGF signaling pathways are also different between chondrogenic and gliogenic specification. Mesencephalic neural crest cells contain developmentally restricted cells with chondrogenic potential (DRCP), such as ectomesenchymal cells that differentiate into chondrocytes, bones, and connective tissue (Le Lièvre and Le Douarin, 1975; Le Douarin and Kalcheim, 1999; Ijuin et al., 2008) , and developmentally restricted cells with (Le Douarin and Dupin, 2003; Ota and Ito, 2006; Ijuin et al., 2008) . The data obtained in this study support the notion that FGFs and Notch signaling do not act on the lineage segregation of DRCP and DRGP from pluripotent neural crest cells but on the specification of DRCP and DRGP to chondrocytes and glia (Ijuin et al., 2008) .
4.
Experimental procedures
Primary cultures
Primary cultures of mesencephalic neural crest cells were prepared from E8.0 (6-to 8-somite stages) ddY mouse embryos (Ito and Morita, 1995; Kubota and Ito, 2000; Ota and Ito, 2003; Nakanishi et al., 2007; Ijuin et al., 2008) . Neural folds at the mesencephalic levels were dissected and cut into fragments. These fragments were explanted in 35-mm culture dishes coated with collagen gel (PureCol). The epithelial components in primary explants were scraped away with a tungsten needle after 48 h, leaving the emigrated mesencephalic neural crest cells on the substratum. The culture medium consisted of 85% a-modified minimum essential medium (a-MEM; Sigma), 10% FBS (Hyclone), 5% CEE, and 50 lg/ml gentamicin (Sigma). The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO 2 . The culture medium was changed every other day. FGF-2 (R&D Systems) was added to the medium at a concentration of 10 ng/ml. U0126 (Promega), U0124 (Calbiochem), PD98059 (Calbiochem), SU5402 (Calbiochem), LY294002 (Calbiochem), LY303511 (Calbiochem), rapamycin (Calbiochem), and SB203580 (Calbiochem) were used at 5 lM, 5 lM, 20 lM, 5 lM, 10 lM, 10 lM, 10 nM, and 10 lM, respectively.
Transfection of the expression vectors
Mouse mesencephalic neural crest cells were transfected with 1-2 lg of the following expression vectors: (1) the pcDNA3 encoding the mouse Notch-IC and a myc epitope (a gift from Dr. J.S. Nye et al., 1994; Foltz et al., 2002) , (2) the pSG5 encoding the human Ets-1 (a gift from Dr. H. Sato; Horikawa et al., 2001) , (3) the pCEP4 encoding the dn human Ets-1 (a gift from Dr. H. Sato; Horikawa et al., 2001) , (4) the pcDNA3 encoding the mouse Ets-1T38A (a gift from Dr. D. Tulasne; Paumelle et al., 2002) . The transfection was performed by using Lipofectamine 2000 (Invitrogen) for the first 24 h or the first 48 h in culture. The transfection efficiency of the vector encoding a myc epitope was estimated by immunostaining with mouse anti-c-myc (9E10) (1:100; Santa Cruz Biotechnology). The efficiencies of the vectors without tags were estimated by co-transfection with the pFP-C1 encoding green fluorescent protein (GFP) (Clontech) and immunostain- 
siRNA preparation
The siRNA duplex forErk-1, Akt-1, and p70S6k were designed on the basis of sequences of Erk-1, Akt-1, and p70S6k published online [GenBank Accession Nos. NM011952.1, NM009652.1, NM028259]. The sequences corresponded to (1) 
Immunostaining
Primary cultures of mouse mesencephalic neural crest cells were fixed with 4% paraformaldehyde (PFA) for 1 h on ice. The cultures ware immunostained with the following primary antibodies: (1) goat anti-collagen type II (1:50; Southern Biotechnology), (2) rabbit anti-GFAP (1:100; DAKO), (3) goat anti-Notch-1 (1:100; Santa Cruz Biotechnology), (4) rabbit anti-Delta (1:200; Santa Cruz Biotechnology), (5) rabbit anti-Erk-1 (1:50-1:100; Abcam), (6) rabbit anti-Akt-1 (1:100; Abcam), (7) rabbit anti-phospho-p70S6k (Thr421/Ser424) (1:100; Cell Signaling Technology), (8) rabbit anti-phospho-p70S6k (Thr389) (1:100; Cell Signaling Technology), and (9) mouse anti-a-tubulin (1:500; Amersham). Primary antibodies were applied for 12 h at 4°C. The cultures were treated with the following secondary antibodies at room temperature for 1 h: (1) rhodamine-conjugated donkey anti-goat IgG (1:50; Chemicon), (2) Alexa-488-conjugated donkey anti-goat IgG (1:500; Molecular Probes), (3) Alexa-488-conjugated donkey anti-rabbit IgG (1:500; Molecular Probes), and (4) Alexa-488-conjugated donkey anti-mouse IgG (1:500; Molecular Probes). Mouse embryos were fixed with 4% PFA for 1 h on ice. Fixed embryos were immersed in gradually increasing concentrations of sucrose solution and embedded in OCT compound (Miles). Cryostat sections were cut at 10 lm and mounted on albumin-coated glass slides. The sections were stained using the following primary antibodies: (1) rabbit anti-phospho-p70S6k (Thr421/Ser424) (1:100), (2) rabbit antiphospho-p70S6k (Thr389) (1:50), and (3) guinea pig anti-SOX10 (1:2000, a gift from Dr. M. Wegner; Maka et al., 2005) . Primary antibodies were applied for 12 h at 4°C. The specimens were treated with the following secondary antibodies at room temperature for 1 h: (1) Alexa-488-conjugated donkey anti-rabbit IgG (1:500 or 1:1000) and (2) rhodamine-conjugated donkey anti-guinea pig IgG (1:100; Chemicon). Finally, the cultures and sections were nuclear-stained with 0.1 lg/ml DAPI (Dojindo). DAPI nuclear staining was particularly important for counting the exact number of immunoreactive cells in the neural crest cell cultures.
BrdU incorporation
BrdU-labeling experiments were performed to estimate cell proliferation in mouse mesencephalic neural crest cell cultures. BrdU (Wako) was prepared as a 1 mM stock solution in a-MEM and was added to the cultures at a final concentration of 50 lM. The cultures were exposed to BrdU for 90 min and were subsequently fixed in 4% PFA on ice for 1 h. BrdU-incorporated cells were detected with mouse monoclonal anti-BrdU antibodies (1:10; Becton-Dickinson). The cultures were nuclear-stained with 0.1 lg/ml DAPI for the total cell count.
